

09/734008

Welcome to STN International! Enter x:x

LOGINID:sssptal200exs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the 'clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985

NEWS EXPRESS October 14 CURRENT WINDOWS VERSION IS V6.01,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:23:43 ON 17 OCT 2002

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 08:23:57 ON 17 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 OCT 2002 HIGHEST RN 462058-01-1

DICTIONARY FILE UPDATES: 16 OCT 2002 HIGHEST RN 462058-01-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 09734008.str

L1 STRUCTURE UPLOADED

=> s 11

SAMPLE SEARCH INITIATED 08:24:20 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 25630 TO ITERATE

3.9% PROCESSED 1000 ITERATIONS

1 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 503051 TO 522149
 PROJECTED ANSWERS: 209 TO 815

L2 1 SEA SSS SAM L1


=> d 12 all

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
 RN 344576-27-8 REGISTRY
 CN Benzoic acid, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, methyl ester, hydrochloride, rel- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H25 N O2 . Cl H
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Ring System Data

Elemental Analysis	Elemental Sequence	Size of the Rings	Ring System Formula	Ring Identifier	RID Occurrence
EA	ES	SZ	RF	RID	Count
C6	C6	6	C6	46.150.18	1
C5-C5-C5	C5-C5-C5	5-5-5	C10	553.3.1	1

Relative stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1

AN 135:46327 CA
 TI Method for the production of substituted norbornylamino derivatives, medicaments containing said compounds and the use thereof as a medicament or a diagnostic reagent

IN Heinelt, Uwe; Lang, Hans-Jochen; Kleemann, Heinz-Werner; Schwark,
Jan-Robert; Wirth, Klaus; Jansen, Hans-Willi
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA German
IC ICM C07C211-38
ICS C07C217-56; A61K031-137
CC 30-10 (Terpenes and Terpenoids)
Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044164	A1	20010621	WO 2000-EP12107	20001201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG DE 19960204 A1 20010628 DE 1999-19960204 19991214 US 2001023257 A1 20010920 US 2000-734008 20001212 NO 2002002801 A 20020809 NO 2002-2801 20020612 PRAI DE 1999-19960204 19991214 WO 2000-EP12107 20001201 GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to substituted norbornylamino derivs. contg.
exo-configured nitrogen and an endo-annelated pentacyclic ring and
exo-configured nitrogen and an exo-annelated pentacyclic ring, e.g. I

[R1,
R2, R3, R4, R5 = H, OH, F, Cl, Br, I, CN, NO2, amidino, CO2R11,
CONR11R12,
SOR11, SOsNR11R12, C1-4-alkyl, C1-4-alkoxy, C1-4-alkoxyalkyl,
C1-4-alkoxyalkoxy, hydroxy-C1-4-alkyl, C3-7-cycloalkoxy, (un)substituted
OPh (up to three of F, Cl, Br, OMe), NH2, C1-4-alkylamino,
di(C1-4-alkyl)amino, amino-C1-4-alkyl, di(C1-4-alkyl)amino-C1-4-alkyl,
C1-4-alkylamino-C1-4-alkyl; R1R2, R2R3, R3R4, R4R5 = O(CH2)nO; R11, R12 =
H, ; A = C1-4-alkylene; B = (un)substituted C5-7-ring with :O, OH,
C1-4-alkoxy, C1-4-alkyl; S1 = free electron pair, C1-4-alkyl; S2 =
C1-4-alkyl, H; when S1 and S2 are both alkyl, the ammonium counter ion,

X-
= pharmaceutically acceptable salt or trifluoroacetate; n = 1, 2; r = 0 -
2; s = 1, 2] and II. Thus, I.cntdot.HCl [R1 = R3 - R5 = S2 = H, R2 =

OMe,
A = B = CH2, S1 = free electron] was prepd. from exo,endo-octahydro-4,7-
methanoinden-5-ylamine (III) via condensation of 3-MeOC6H4CHO in PhMe

contg. catalytic p-TsOH followed by redn. with NaBH₄ in MeOH and acidification with HCl in MeOH. Said derivs. are esp. suitable as anti-hypertensive agents for reducing or preventing ischemia-induced damage, as medicaments for use in surgical procedures for treating ischemias of the nervous system, of a cerebrovascular accident and of a cerebral edema. The derivs. are also suitable for treating shock, an impaired respiratory impulse, snoring, or for use as a laxative, as an agent against ectoparasites, in the prophylaxis of gall stones, as an anti-atherosclerotic agent, as an agent for treating late complications

of diabetes, or for treating cancerous illnesses, fibrotic disorders, endothelial dysfunction and organ hypertrophies and hyperplasias. Said derivs. act as inhibitors of the cellular sodium-proton-antiporter. They also influence serum lipoproteins and can thus be used in the prophylaxis and reversal of atherosclerotic changes. Thus, I.cntdot.HCl [R1 = R3 -

R5 = S2 = H, R2 = OMe, A = B = CH₂, S1 = free electron] was tested for its diuretic (none orally in rats) and NHE3 activity (IC₅₀ = 0.81 .mu.M).

ST pentacyclic annelated norbornylamine deriv prepn biol activity; methanoindenylamine octahydro deriv prepn condensation benzaldehyde methoxybenzaldehyde; diuretic pentacyclic annelated norbornylamine deriv prepn; NHE3 activity diuretic pentacyclic annelated norbornylamine deriv; sodium proton antiporter inhibitor pentacyclic annelated norbornylamine deriv prepn; serum lipoprotein regulator pentacyclic annelated norbornylamine deriv prepn; atherosclerotic change medicament pentacyclic annelated norbornylamine deriv prepn; antihypertensive pentacyclic annelated norbornylamine deriv prepn

IT Structure-activity relationship
(diuretic; prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(hydrogen ion-sodium-exchanging, cellular antiporter inhibitor; prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT Antihypertensives
Diuretics
(prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT Atherosclerosis
(prophylaxis and reversal medicaments; prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT Lipoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(serum, regulators; prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT 344576-13-2P 344576-14-3P 344576-96-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted norbornylamino derivs. for use as a

antihypertensive agent or a diagnostic reagent)

IT 344577-00-0P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT 344576-09-6P 344576-10-9P 344576-11-0P 344576-12-1P 344576-16-5P
 344576-17-6P 344576-18-7P 344576-19-8P 344576-20-1P 344576-21-2P
 344576-22-3P 344576-23-4P 344576-24-5P 344576-25-6P 344576-26-7P
 344576-27-8P 344576-28-9P 344576-30-3P 344576-32-5P 344576-34-7P
 344576-35-8P 344576-37-0P 344576-38-1P 344576-40-5P 344576-41-6P
 344576-42-7P 344576-43-8P 344576-44-9P 344576-45-0P 344576-46-1P
 344576-47-2P 344576-48-3P 344576-49-4P 344576-50-7P 344576-51-8P
 344576-52-9P 344576-53-0P 344576-54-1P 344576-56-3P 344576-57-4P
 344576-59-6P 344576-60-9P 344576-62-1P 344576-63-2P 344576-64-3P
 344576-65-4P 344576-66-5P 344576-67-6P 344576-68-7P 344576-69-8P
 344576-70-1P 344576-71-2P 344576-72-3P 344576-73-4P 344576-74-5P
 344576-75-6P 344576-76-7P 344576-77-8P 344576-78-9P 344576-80-3P
 344576-82-5P 344576-83-6P 344576-84-7P 344576-85-8P 344576-86-9P
 344576-87-0P 344576-88-1P 344576-94-9P 344576-95-0P 344577-06-6P
 344577-07-7P 344577-08-8P 344577-09-9P 344577-10-2P 344577-11-3P
 344577-12-4P 344577-13-5P 344577-14-6P 344577-15-7P 344577-16-8P
 344577-17-9P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT 77-73-6, Dicyclopentadiene 85-41-6, Phthalimide 99-61-6,
 3-Nitrobenzaldehyde 99-64-9, 3-(Dimethylamino)benzoic acid 100-83-4,
 3-Hydroxybenzaldehyde 395-44-8, 2-(Trifluoromethyl)benzyl bromide
 456-48-4, 3-Fluorobenzaldehyde 586-37-8 587-04-2,
 3-Chlorobenzaldehyde
 591-31-1, 3-Methoxybenzaldehyde 625-95-6, 3-Iodotoluene 1798-09-0,
 3-Methoxyphenylacetic acid 3132-99-8, 3-Bromobenzaldehyde 4453-90-1,
 Benzonorbornadiene 6482-24-2, 1-Bromo-2-methoxyethane 10516-71-9,
 3-(3-Methoxyphenyl)propionic acid 13380-94-4,
 Tricyclo[5.2.1.0^{2,6}]decan-8-one 24964-64-5, 3-Cyanobenzaldehyde
 32085-88-4, 3,5-Difluorobenzaldehyde 72403-63-5,
 exo-5-Isothiocyanato-5,6-dihydro-endo-dicyclopentadiene 344577-05-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

IT 7142-70-3P 18530-42-2P 18530-46-6P, exo,endo-Octahydro-4,7-methanoinden-5-ylamine 18530-47-7P,
 exo,exo-Octahydro-4,7-methanoinden-5-ylamine 49617-83-6P 62624-26-4P, exo-(1,2,3,4-Tetrahydro-1,4-methanonaphthalin-2-yl)amine 65839-06-7P 73244-50-5P 73335-94-1P,
 endo,exo-Octahydro-4,7-methanoinden-5-ylamine 114062-14-5DP, isomers
 344576-89-2P 344576-90-5P 344576-92-7P 344576-93-8P 344576-97-2P
 344576-99-4P 344577-01-1P 344577-02-2P 344577-03-3P 344577-04-4P
 344577-19-1P 344920-95-2P 344920-96-3P 344920-97-4P 344920-98-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(prepn. of substituted norbornylamino derivs. for use as a
antihypertensive agent or a diagnostic reagent)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

- (1) Druckrey, E; US 4024274 A 1977 CAPLUS
- (2) Hoechst Ag; EP 0825178 A 1998 CAPLUS
- (3) Magainin Pharma; WO 9640151 A 1996 CAPLUS

=> s ll full

FULL SEARCH INITIATED 08:25:25 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 516633 TO ITERATE

77.4% PROCESSED 400000 ITERATIONS

112 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.05

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 516633 TO 516633

PROJECTED ANSWERS: 112 TO 180

L3 112 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
145.41	145.62

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.59	-0.59

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 08:25:49 ON 17 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Oct 2002 VOL 137 ISS 16

FILE LAST UPDATED: 16 Oct 2002 (20021016/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s 13

L4 11 L3

=> d 14 ibib abs hitstr 1-11

L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:503263 CAPLUS

DOCUMENT NUMBER: 137:78858

TITLE: Preparation of methanoindenylaminomethylheterocycles and related compounds as inhibitors of the sodium-proton exchanger.

INVENTOR(S): Heinelt, Uwe; Lang, Hans-Jochen; Wirth, Klaus; Jansen,

Hans-Willi

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: Ger. Offen., 20 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10063294	A1	20020704	DE 2000-10063294	20001219
WO 2002066431	A1	20020829	WO 2001-EP14422	20011207


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DE 2000-10063294 A 20001219

OTHER SOURCE(S): CASREACT 137:78858; MARPAT 137:78858

GI



AB Title compds. [I; A = alkylene; T = H, alkyl; B = (substituted) (unsatd.)
exo- or endo 5-6 membered ring; X = (unsatd.) 5-6 membered heterocyclyl;

n

= 0-4; with a proviso], were prepd. Thus, endo/exo-octahydro-4,7-methanoinden-5-ylamine (prepn. given), pyridine-3-carboxaldehyde, and p-toluenesulfonic acid were refluxed in PhMe through a water separator. The residue in MeOH was treated with NaBH₄ followed by acidification with HCl to give endo/exo-(octahydro-4,7-methanoinden-5-yl)pyridin-3-ylmethylamine hydrochloride. The latter showed rat Na⁺/H⁺ exchanger 3 (NHE3) inhibitory activity with IC₅₀ = 0.34 .mu.M.

IT **344576-93-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of methanoindenylaminomethylheterocycles and related compds.

as


inhibitors of the sodium-proton exchanger)

RN 344576-93-8 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione,

2-[(3aR,4R,5S,7R,7aR)-octahydro-4,7-methano-1H-inden-5-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:452994 CAPLUS

DOCUMENT NUMBER: 135:46327

TITLE: Method for the production of substituted norbornylamino derivatives, medicaments containing said compounds and the use thereof as a medicament or a diagnostic reagent

INVENTOR(S): Heinelt, Uwe; Lang, Hans-Jochen; Kleemann, Heinz-Werner; Schwark, Jan-Robert; Wirth, Klaus; Jansen, Hans-Willi

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

applicants

WO 2001044164 A1 20010621 WO 2000-EP12107 20001201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
DE 19960204 A1 20010628 DE 1999-19960204 19991214
US 2001023257 A1 20010920 US 2000-734008 20001212
NO 2002002801 A 20020809 NO 2002-2801 20020612
PRIORITY APPLN. INFO.: DE 1999-19960204 A 19991214
WO 2000-EP12107 W 20001201
OTHER SOURCE(S): MARPAT 135:46327
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to substituted norbornylamino derivs. contg.
exo-configured nitrogen and an endo-annelated pentacyclic ring and
exo-configured nitrogen and an exo-annelated pentacyclic ring, e.g. I
[R1,
R2, R3, R4, R5 = H, OH, F, Cl, Br, I, CN, NO2, amidino, CO2R11,
CONR11R12,
SOR11, SOsNR11R12, C1-4-alkyl, C1-4-alkoxy, C1-4-alkoxyalkyl,
C1-4-alkoxyalkoxy, hydroxy-C1-4-alkyl, C3-7-cycloalkoxy, (un)substituted
OPh (up to three of F, Cl, Br, OMe), NH2, C1-4-alkylamino,
di(C1-4-alkyl)amino, amino-C1-4-alkyl, di(C1-4-alkyl)amino-C1-4-alkyl,
C1-4-alkylamino-C1-4-alkyl; R1R2, R2R3, R3R4, R4R5 = O(CH2)nO; R11, R12 =
H, ; A = C1-4-alkylene; B = (un)substituted C5-7-ring with :O, OH,
C1-4-alkoxy, C1-4-alkyl; S1 = free electron pair, C1-4-alkyl; S2 =
C1-4-alkyl, H; when S1 and S2 are both alkyl, the ammonium counter ion,
X-
= pharmaceutically acceptable salt or trifluoroacetate; n = 1, 2; r = 0 -
2; s = 1, 2] and II. Thus, I.cntdot.HCl [R1 = R3 - R5 = S2 = H, R2 =
OMe,
A = B = CH2, S1 = free electron] was prepd. from exo,endo-octahydro-4,7-
methanoinden-5-ylamine (III) via condensation of 3-MeOC6H4CHO in PhMe
contg. catalytic p-TsOH followed by redn. with NaBH4 in MeOH and
acidification with HCl in MeOH. Said derivs. are esp. suitable as
anti-hypertensive agents for reducing or preventing ischemia-induced
damage, as medicaments for use in surgical procedures for treating
ischemias of the nervous system, of a cerebrovascular accident and of a
cerebral edema. The derivs. are also suitable for treating shock, an
impaired respiratory impulse, snoring, or for use as a laxative, as an
agent against ectoparasites, in the prophylaxis of gall stones, as an
anti-atherosclerotic agent, as an agent for treating late complications
of
diabetes, or for treating cancerous illnesses, fibrotic disorders,
endothelial dysfunction and organ hypertrophies and hyperplasias. Said
derivs. act as inhibitors of the cellular sodium-proton-antiporter. They

also influence serum lipoproteins and can thus be used in the prophylaxis and reversal of atherosclerotic changes. Thus, I.cntdot.HCl [R1 = R3 -

R5

= S2 = H, R2 = OMe, A = B = CH2, S1 = free electron] was tested for its diuretic (none orally in rats) and NHE3 activity (IC50 = 0.81 .mu.M).

IT **344576-13-2P 344576-14-3P 344576-96-1P**

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological


study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

RN 344576-13-2 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-14-3 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, hydrochloride, (3aS,4R,5S,7R,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




HCl

RN 344576-96-1 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

IT 344577-00-0P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological


study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of substituted norbornylamino derivs. for use as a antihypertensive agent or a diagnostic reagent)

RN 344577-00-0 CAPLUS

CN Benzoic acid, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, butyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 344576-09-6P 344576-12-1P 344576-16-5P
 344576-17-6P 344576-18-7P 344576-19-8P
 344576-20-1P 344576-21-2P 344576-22-3P
 344576-23-4P 344576-24-5P 344576-25-6P
 344576-26-7P 344576-27-8P 344576-28-9P
 344576-30-3P 344576-32-5P 344576-34-7P
 344576-35-8P 344576-37-0P 344576-38-1P
 344576-40-5P 344576-41-6P 344576-42-7P


344576-43-8P 344576-47-2P 344576-48-3P
 344576-49-4P 344576-50-7P 344576-51-8P
 344576-52-9P 344576-53-0P 344576-54-1P
 344576-56-3P 344576-57-4P 344576-59-6P
 344576-60-9P 344576-62-1P 344576-63-2P
 344576-64-3P 344576-65-4P 344576-66-5P
 344576-67-6P 344576-68-7P 344576-69-8P
 344576-70-1P 344576-71-2P 344576-72-3P
 344576-73-4P 344576-74-5P 344576-75-6P
 344576-76-7P 344576-77-8P 344576-78-9P
 344576-80-3P 344576-82-5P 344576-83-6P
 344576-84-7P 344576-85-8P 344576-86-9P
 344576-87-0P 344576-88-1P 344577-06-6P
 344577-07-7P 344577-08-8P 344577-09-9P
 344577-10-2P 344577-11-3P 344577-12-4P
 344577-13-5P 344577-15-7P 344577-16-8P
 344577-17-9P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of substituted norbornylamino derivs. for use as a
 antihypertensive agent or a diagnostic reagent)

RN 344576-09-6 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, N-[(3-chlorophenyl)methyl]octahydro-,
 hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-12-1 CAPLUS


CN 4,7-Methano-1H-inden-2-ol, octahydro-5-[[[(3-methoxyphenyl)methyl]amino]-,
 (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344576-16-5 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, hydrochloride, (3aR,4R,5R,7R,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-17-6 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, hydrochloride, (3aR,4S,5S,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




HCl

RN 344576-18-7 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-, hydrochloride, (3aR,4R,5S,7R,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-19-8 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, N-[(3-fluorophenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-20-1 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, N-[(3,5-difluorophenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-21-2 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[1-(3-methoxyphenyl)ethyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-22-3 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, N-[(3-bromophenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 344576-23-4 CAPLUS
 CN Benzoic acid, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 344576-24-5 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[3-(2-methoxyethoxy)phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




HCl

RN 344576-25-6 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-iodophenyl)methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-26-7 CAPLUS

CN Benzonitrile, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-27-8 CAPLUS

CN Benzoic acid, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, methyl ester, hydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-28-9 CAPLUS
 CN Benzenemethanol,
 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-30-3 CAPLUS
 CN Benzamide, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344576-29-0
 CMF C18 H24 N2 O


Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344576-32-5 CAPLUS


CN 1,3-Benzenedimethanamine, N-[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]-, rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344576-31-4

CMF C18 H26 N2


Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 344576-34-7 CAPLUS


CN Benzenecarboximidamide, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344576-33-6

CMF C18 H25 N3


Relative stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 344576-35-8 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-nitrophenyl)methyl]-, monohydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-37-0 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, N-[(3-aminophenyl)methyl]octahydro-,
 (3aR,4S,5R,7S,7aR)-rel-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 344576-36-9
 CMF C17 H24 N2

Relative stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 344576-38-1 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-N-methyl-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-40-5 CAPLUS
 CN 4,7-Methano-1H-inden-5-aminium,
 octahydro-N-[(3-methoxyphenyl)methyl]-N,N-
 dimethyl-, (3aR,4S,5R,7S,7aR)-rel-, salt with trifluoroacetic acid (1:1)
 (9CI) (CA INDEX NAME)

CM 1


CRN 344576-39-2
 CMF C20 H30 N O

Relative stereochemistry.



CM 2


CRN 14477-72-6
 CMF C2 F3 O2



RN 344576-41-6 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, N-[(3-fluorophenyl)methyl]octahydro-, hydrochloride, (3aR,4R,5S,7R,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-42-7 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[2-(trifluoromethyl)phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-43-8 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, N-[[3-(dimethylamino)phenyl]methyl]octahydro-, monohydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-47-2 CAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(4-methoxyphenyl)methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-48-3 CAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(2-methoxyphenyl)methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-49-4 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, N-[(2,5-dimethoxyphenyl)methyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-50-7 CAPLUS
 CN 1,3-Benzodioxole-5-methanamine, N-[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 344576-51-8 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, N-[(3,4-dimethoxyphenyl)methyl]octahydro-,
 (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 344576-52-9 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, N-[(2,4-dimethoxyphenyl)methyl]octahydro-,
 hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




HCl



● HCl

RN 344576-53-0 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine,
 N-[(4-fluoro-3-methoxyphenyl)methyl]octahydro-
 o-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-54-1 CAPLUS
 CN Phenol, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-56-3 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[3-(trifluoromethoxy)phenyl]methyl]-, (3aR,4S,5R,7S,7aR)-rel-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 344576-55-2
 CMF C18 H22 F3 N O

Relative stereochemistry.



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 344576-57-4 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, N-[(3-ethoxyphenyl)methyl]octahydro-,

hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-59-6 CAPLUS
CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]-, (3aR,4S,5R,7S,7aR)-rel-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 344576-58-5
CMF C19 H23 F4 N O


Relative stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2





RN 344576-60-9 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[3-(1-methylethoxy)phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel-(9CI)
 (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-62-1 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine,
 N-[(3-ethoxy-4-methoxyphenyl)methyl]octahydr
 o-, (3aR,4S,5R,7S,7aR)-rel-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 344576-61-0
 CMF C20 H29 N O2


Relative stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 344576-63-2 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methylphenyl)methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-64-3 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[3-(trifluoromethyl)phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-65-4 CAPLUS
 CN Benzoic acid,
 2,6-dimethoxy-3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-
 1H-inden-5-yl]amino]methyl]-, methyl ester, hydrochloride, rel- (9CI)
 (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-66-5 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine,
 octahydro-N-[(3,4,5-trifluorophenyl)methyl]-
 , hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-67-6 CAPLUS
 CN Benzenesulfonamide,
 2-chloro-5-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-
 1H-inden-5-yl]amino]methyl]-, monohydrochloride, rel- (9CI) (CA INDEX
 NAME)


Relative stereochemistry.



● HCl

RN 344576-68-7 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine,
 N-[[3-(cyclopentyloxy)phenyl]methyl]octahydr
 o-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-69-8 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine,
 N-[[3-(cyclobutyloxy)phenyl]methyl]octahydro-
 , hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-70-1 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine,
 N-[[3-(cyclohexyloxy)phenyl]methyl]octahydro-
 , hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-71-2 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, N-[(3,4-difluorophenyl)methyl]octahydro-,
 hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-72-3 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, N-[(3,5-dimethoxyphenyl)methyl]octahydro-,
 hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-73-4 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, N-[(3-ethylphenyl)methyl]octahydro-,
 hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-74-5 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, N-[(2-fluorophenyl)methyl]octahydro-,
 hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-75-6 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[2-
 [(trifluoromethyl)thio]phenyl]methyl]-, hydrochloride,
 (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-76-7 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[4-
 (trifluoromethoxy)phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel-
 (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-77-8 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine,
 octahydro-N-[[3-(methylthio)phenyl]methyl]-,
 hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-78-9 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[4-(trifluoromethyl)phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-80-3 CAPLUS
 CN Phenol,
 2-methoxy-4-nitro-6-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, rel-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 344576-79-0
 CMF C18 H24 N2 O4

Relative stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 344576-82-5 CAPLUS
CN 4,7-Methano-1H-inden-5-amine,
N-[[3-(3,4-dichlorophenoxy)phenyl]methyl]oct
ahydro-, (3aR,4S,5R,7S,7aR)-rel-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 344576-81-4
CMF C23 H25 Cl2 N O

Relative stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 344576-83-6 CAPLUS
CN 4,7-Methano-1H-inden-5-amine, N-[1-(3-chlorophenyl)ethyl]octahydro-,
hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-84-7 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[1-(3-methylphenyl)ethyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-85-8 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[1-[4-methoxy-3-(methylsulfonyl)phenyl]ethyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-86-9 CAPLUS

CN Benzenesulfonamide, 2-chloro-5-[1-[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]ethyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 344576-87-0 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, N-[1-[4-chloro-3-(methylsulfonyl)phenyl]ethyl]octahydro-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344576-88-1 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[[3-(methylsulfonyl)phenyl]methyl]-, hydrochloride, (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 344577-06-6 CAPLUS
 CN Benzoic acid, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, ethyl ester, hydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 344577-07-7 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, N-[(3-chlorophenyl)methyl]octahydro-,
 (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 344577-08-8 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, N-[(3-fluorophenyl)methyl]octahydro-,
 (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 344577-09-9 CAPLUS
 CN 1,3-Benzodioxole-5-methanamine, N-[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 344577-10-2 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-,
 (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 344577-11-3 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-,
 (3aR,4R,5S,7R,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 344577-12-4 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-,
 (3aR,4S,5R,7S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 344577-13-5 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[1-(3-methoxyphenyl)ethyl]-,
 (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 344577-15-7 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, N-[(3,5-difluorophenyl)methyl]octahydro-,
 (3aR,4S,5R,7S,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 344577-16-8 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, N-[(3-fluorophenyl)methyl]octahydro-,
 (3aR,4R,5S,7R,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 344577-17-9 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-[(3-methoxyphenyl)methyl]-,
 (3aR,4R,5S,7R,7aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **344576-93-8P 344577-01-1P 344577-19-1P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of substituted norbornylamino derivs. for use as a
 antihypertensive agent or a diagnostic reagent)
 RN 344576-93-8 CAPLUS
 CN 1H-Isoindole-1,3(2H)-dione,
 2-[(3aR,4R,5S,7R,7aR)-octahydro-4,7-methano-1H-
 inden-5-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 344577-01-1 CAPLUS
 CN Benzenecarboximidic acid,
 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-

inden-5-yl]amino]methyl]-, ethyl ester, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl

RN 344577-19-1 CAPLUS


CN Benzonitrile, 3-[[[(3aR,4S,5R,7S,7aR)-octahydro-4,7-methano-1H-inden-5-yl]amino]methyl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 344577-18-0

CMF C18 H22 N2


Relative stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2





REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:824211 CAPLUS

DOCUMENT NUMBER: 134:4764

TITLE: Preparation of 3-(benzoylamino)propionic acid
derivatives as glucagon antagonists/inverse agonists

INVENTOR(S): Ling, Anthony; Plewe, Michael Bruno; Truesdale, Larry
Kenneth; Lau, Jesper; Madsen, Peter; Sams, Christian;
Behrens, Carsten; Vagner, Josef; Christensen, Inge
Thoger; Lundt, Behrend Frederik; Sidelmann, Ulla
Grove; Thogersen, Henning

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Agouron Pharmaceuticals, Inc.

SOURCE: PCT Int. Appl., 564 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069810	A1	20001123	WO 2000-DK264	20000516
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1183229	A1	20020306	EP 2000-926725	20000516
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 2000010651	A	20020319	BR 2000-10651	20000516
NO 2001005607	A	20020117	NO 2001-5607	20011116
PRIORITY APPLN. INFO.:			DK 1999-684	A 19990517
			DK 2000-478	A 20000321
			WO 2000-DK264	W 20000516

OTHER SOURCE(S): MARPAT 134:4764

GI



AB The title compds. [I; V = CO₂R₂, CONR₂R₃, CONR₂OR₃, etc. (wherein R₂, R₃ = H, alkyl); A = (CH₂)_n(CR₈R₉)_bNR₇, (CR₈R₉)_b(CH₂)_nNR₇, (CR₈R₉)_b(CH₂)_n, etc. (b = 0-1; n = 0-3; R₇ = H, alkyl, (cycloalkyl)alkyl; R₈, R₉ = H, alkyl); Y = CO, SO₂, O, a bond; Z = (un)substituted phenylene, divalent radical derived from 5-6 membered heteroarom. ring contg. 1-2 heteroatoms selected


from N, O and S; or AYZ together = II; R₁ = H, alkyl; X = CO(CR₁₃R₁₄)_r(CH₂)_s, SO₂(CR₁₃R₁₄)_r(CH₂)_s, CO₂(CR₁₃R₁₄)_r(CH₂)_s, etc. (r = 0-1; s = 0-3; R₁₃, R₁₄ = H, alkyl); D = (un)substituted Ph, pyridyl, cyclopropyl, etc.; E = (un)substituted quinolinyl, 2,5-dioxopiperidinyl, biphenylalkyl, etc.] which act to antagonize the action of the glucagon hormone on the glucagon receptor (data given), and therefore may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity, were prepd. and formulated. E.g., a multi-step solid phase synthesis of III was given. Compds. I are effective at 0.05-10 mg/kg/day.

IT **307986-79-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of 3-(benzoylamino)propionic acid derivs. as glucagon antagonists/inverse agonists)


RN 307986-79-4 CAPLUS

CN Benzoic acid, 4-(trifluoromethoxy)-, 2-[[[4-[[[2-carboxyethyl]amino]carbonyl]phenyl]methyl]-2-(octahydro-4,7-methano-1H-inden-5-yl)hydrazide (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:811714 CAPLUS
DOCUMENT NUMBER: 130:138974
TITLE: Unusual photochemical behavior of 5-amino-endo-dicyclopentadien-3-ones
AUTHOR(S): Bakkeren, Frank J. A. D.; Schroer, Frank; De Gelder, Rend; Klunder, Antonius J. H.; Zwanenburg, Binne
CORPORATE SOURCE: Departments of Organic Chemistry and Inorganic Chemistry, NSR Center for Molecular Structure, Design and Synthesis, University of Nijmegen, Nijmegen, 6525 ED, Neth.
SOURCE: Tetrahedron Letters (1998), 39(51), 9527-9530
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Irradn. of 5-amino-substituted
endo-tricyclo[5.2.1.0.6]deca-4,8-dien-3-ones
[I; R1,R2 given: H,cyclohexyl; H,benzyl (Bn); (R1R2)= morpholino] did not
lead to the anticipated [.pi.2 + .pi.2]-photocyclization, thus not
affording bridgehead 1,3-bishomocubyl amines (II; R1,R2 as above).

Instead, an unexpected photoredn. of the norbornene C8-C8 double bond was obsd., which based on d-labeling studies involves a photoelectron transfer

process. The desired $[\pi.2 + \pi.2]$ -photocyclization could be affected by N-acylation of the amino function in I ($R_1 = H$, $R_2 = Bn$) furnishing 4-amido-substituted 1,3-bishomocubanonones (III; $R = Me, MeO, Bn, OBn$).


IT 220006-06-4P 220006-07-5P 220006-08-6P
220006-09-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(photoreactions of amino-substituted endo tricyclodecadienones)

RN 220006-06-4 CAPLUS


CN Acetamide,

N-(octahydro-5-oxo-1,2,4-metheno-1H-cyclobuta[cd]pentalen-1-yl)-
N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 220006-07-5 CAPLUS

CN Carbamic acid, (octahydro-5-oxo-1,2,4-metheno-1H-cyclobuta[cd]pentalen-1-yl)(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 220006-08-6 CAPLUS

CN Benzeneacetamide, N-(octahydro-5-oxo-1,2,4-metheno-1H-cyclobuta[cd]pentalen-1-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 220006-09-7 CAPLUS
 CN Carbamic acid, (octahydro-5-oxo-1,2,4-metheno-1H-cyclobuta[cd]pentalen-1-yl)(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1991:35854 CAPLUS
 DOCUMENT NUMBER: 114:35854
 TITLE: Synthesis of certain spirohexahydro-4,7-methanoindanpiperazine derivatives as analgesics
 AUTHOR(S): Aboul-Enein, M. N.; Maklout, A. M. A.; El-Azzouny, A. A.
 CORPORATE SOURCE: Lab. Pharm. Sci., Natl. Res. Cent., Dokki, Egypt
 SOURCE: Scientia Pharmaceutica (1990), 58(3), 263-71
 CODEN: SCPHA4; ISSN: 0036-8709
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



I



II, X=NH

III, X=O

AB Title compds. (I and II, R = Ph, 4-MeC6H4, 4-MeOC6H4, PhCH2), were prepd. from the corresponding aminohexahydro-4,7-methanoindan-5-carbonitriles by modified Strecker synthesis, acid hydrolysis, cyanomethylation and reaction with ethylenediamine hydrolysis and tested for their analgesic activity in a mouse hot-plate test. Compd. I (R = 4-MeOC6H4) exhibited the highest activity with an ED50 of 9.9 mg/kg compared to morphine-HCl with an ED50 of 7.3 mg/kg. Structure-activity relations for I and II are discussed.

IT 131466-10-9P 131466-14-3P 131466-18-7P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological)


study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and analgesic activity of, structure in relation to)

RN 131466-10-9 CAPLUS

CN Spiro[imidazo[1,2-a]pyrazine-6(5H),5'-[4,7]methano[5H]inden]-5-one,
1',2,2',3,3',3'a,4',6',7,7',7'a,8-dodecahydro-7-(phenylmethyl)- (9CI)


(CA

INDEX NAME)




RN 131466-14-3 CAPLUS

CN Spiro[4,7-methano-5H-indene-5,2'(3'H)-pyrazin]-3'-one,
5'-amino-1,1',2,3,3a,4,6,6',7,7a-decahydro-1'-(phenylmethyl)- (9CI) (CA
INDEX NAME)



RN 131466-18-7 CAPLUS

CN Spiro[4,7-methano-5H-indene-5,2'-piperazine]-3',5'-dione,
octahydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)




IT **131466-26-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. and cyanomethylation of)

RN 131466-26-7 CAPLUS

CN 4,7-Methano-1H-indene-5-carboxamide, octahydro-5-[(phenylmethyl)amino]-
(9CI) (CA INDEX NAME)




IT **131466-30-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclization of)

RN 131466-30-3 CAPLUS

CN 4,7-Methano-1H-indene-5-carboxamide,
5-[(cyanomethyl)(phenylmethyl)amino]o
ctahydro- (9CI) (CA INDEX NAME)




IT **131466-22-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and hydrolysis of, carboxamide formation in)

RN 131466-22-3 CAPLUS

CN 4,7-Methano-1H-indene-5-carbonitrile, octahydro-5-[(phenylmethyl)amino]-
(9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1987:438842 CAPLUS

DOCUMENT NUMBER: 107:38842


TITLE: Electrochemical 1-adamantylation and
tetrahydro-exo-dicyclopentadien-9-ylation of
azomethines

AUTHOR(S): Hess, U.; Lieberenz, C.; Feuerherd, B.

CORPORATE SOURCE: Sek. Chem., Humboldt-Univ. Berlin, Berlin, DDR-1040,
Ger. Dem. Rep.

SOURCE: J. Prakt. Chem. (1986), 328(1), 7-20
CODEN: JPCEAO; ISSN: 0021-8383

DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 107:38842
 GI




AB Azomethine adducts I (R = Ph, p-tolyl, 2-pyridyl, 2-quinolyl; R1 = H, Me; R2 = Me, Ph, arylalkyl) and II (R = Ph, p-anisyl) were prepd. by electrochem. reactions of azomethines with 1-bromoadamantane and 9-bromotetrahydro-exo-dicyclopentadiene. In the SET mechanism bridgehead radicals couple with azomethine anion radicals at the position of highest unpaired electron d., normally the C of the C:N group.

IT **89516-07-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 89516-07-4 CAPLUS

CN 4,7-Methano-1H-inden-5-amine, octahydro-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1985:197548 CAPLUS

DOCUMENT NUMBER: 102:197548

TITLE: Synthesis and pharmacological activity of derivatives of exo-trimethylenenorbornane. V

AUTHOR(S): Longobardi, M.; Schenone, P.; Bargagna, A.; Matera, C.; Rossi, F.; Marmo, E.

CORPORATE SOURCE: Ist. Sci. Farm., Univ. Genova, Genoa, Italy



SOURCE: Farmaco, Ed. Sci. (1985), 40(3), 162-9

CODEN: FRPSAX; ISSN: 0430-0920

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Seven amides I (R = CH₂Cl, Me, cyclopropyl, CH:CHPh, Ph, 4-NO₂C₆H₄, and 4-H₂NC₆H₄) and 6 glycinamides II (R = NEt₂, NMe(CH₂)₂NMe₂, pyrrolidino, piperidino, morpholino, N'-methylpiperazino) derived from N-phenyl-exo-5,6-trimethylenenorbornan-2-endo-amine [96356-45-5] were prepd. and tested for pharmacol. activity. All of the I derivs. showed moderate hypotensive activity whereas some of the I and II derivs. had weak local anesthetic and antiarrhythmic activity. The effects of the compds. on heart rate are also described.

IT **96356-34-2P 96356-36-4P**


RL: BAC (Biological activity or effector, except adverse); BPR (Biological

process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (prepn. and pharmacol. of)

RN 96356-34-2 CAPLUS

CN Benzamide, N-(octahydro-4,7-methano-1H-inden-5-yl)-N-phenyl-, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 96356-36-4 CAPLUS

CN Benzamide, 4-amino-N-(octahydro-4,7-methano-1H-inden-5-yl)-N-phenyl-, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT **96356-35-3P**RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and redn. of)

RN 96356-35-3 CAPLUS

CN Benzamide, 4-nitro-N-(octahydro-4,7-methano-1H-inden-5-yl)-N-phenyl-,
(3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1984:156514 CAPLUS

DOCUMENT NUMBER: 100:156514

TITLE: 9(10)-Substituted 9,10-dihydro- and
tetrahydro-exo-dicyclopentadienes

INVENTOR(S): Hess, Ulrich; Feuerherd, Bernd

PATENT ASSIGNEE(S): Humboldt-Universitaet zu Berlin, Ger. Dem. Rep.

SOURCE: Ger. (East), 11 pp.

CODEN: GEXXA8

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 202863	A1	19831005	DD 1981-235451	19811205

GI




AB The dicyclopentadienes I (R = N heterocyclic, aminomethyl, tertiary amino) and their 1,2- and 2,3-didehydro derivs. were prepd. Thus, I (R = Br) was electrolyzed with quinoline to give 36% I (R = 2-quinolyl).

IT **89516-07-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)
 RN 89516-07-4 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1983:525424 CAPLUS
 DOCUMENT NUMBER: 99:125424
 TITLE: 2,3-Dihydroperimidines as antioxidants for lubricants
 INVENTOR(S): Malherbe, Roger F.
 PATENT ASSIGNEE(S): Ciba-Geigy Corp. , USA
 SOURCE: U.S., 5 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4389321	A	19830621	US 1981-334860	19811228
EP 83311	A2	19830706	EP 1982-810562	19821222
EP 83311	A3	19840725		
EP 83311	B1	19860813		
R: DE, FR, GB, IT				
JP 58118896	A2	19830715	JP 1982-234946	19821228
PRIORITY APPLN. INFO.:			US 1981-334860	19811228

AB Derivs. of 2,3-dihydroperimidine show very high oxidn. stabilizer activity and good soly. in mineral and synthetic lubricating oils. Thus, when 0.25 wt.% 2,3-dihydroperimidine-2-spiro (4-tert-amylcyclohexane [87103-31-9] (prepd. by reacting 1,8-diaminonaphthalene with 4-tert-amylcyclohexanone in toluene under reflux) was added to a mineral oil, it gave 660 mm oxidn. time in the Rotary Bomb Oxidn. test vs. 114 min when a com. additive was used.

IT **87103-35-3P**
 RL: PREP (Preparation)
 (prepn. of, for use as lubricating oil antioxidant)
 RN 87103-35-3 CAPLUS
 CN Spiro[4,7-methano-5H-indene-5,2' (3'H)-[1H]perimidine], 1,2,3,3a,4,6,7,7a-octahydro- (9CI) (CA INDEX NAME)




L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1980:163608 CAPLUS
 DOCUMENT NUMBER: 92:163608
 TITLE: Synthesis and pharmacological activity of derivatives
 of exo-trimethylenenorbornane. I
 AUTHOR(S): Bondavalli, F.; Lanteri, S.; Longobardi, M.;
 Schenone,
 P.
 CORPORATE SOURCE: Ist. Sci. Farm., Univ. Genova, Genoa, Italy
 SOURCE: Farmaco, Ed. Sci. (1979), 34(11), 945-51
 CODEN: FRPSAX; ISSN: 0430-0920
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB LiAlH₄ redn. of oxime I (RR₁ = NOH) gave endo-amine I (R = H, R₁ = NH₂),
 which was acylated with ClCOR₂ (R₂ = Me, Ph, C₆H₄NO₂-p, C₆H₂(OMe)₃,
 CHPh₂,
 cyclopropyl) to give I (R = H, R₁ = NHCOR₂), whose redn. gave amines I (R
 = H, R₁ = NHCH₂R₂). I (R = H; R₁ = NHAc, NHCOC₆H₄NH₂-4,
 cyclopropylcarboxamido) had weak depressant activity and I (R = H, R₁ =
 cyclopropylmethylamino) was a convulsant.
 IT **73336-03-5P 73336-04-6P 73336-05-7P**
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (prepn. and pharmacol. activities of)
 RN 73336-03-5 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, octahydro-N-(phenylmethyl)-,
 (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 73336-04-6 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine, N-[(4-aminophenyl)methyl]octahydro-,
 dihydrochloride, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI)
 (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl


RN 73336-05-7 CAPLUS
 CN 4,7-Methano-1H-inden-5-amine,
 octahydro-N-[(3,4,5-trimethoxyphenyl)methyl]-
 , hydrochloride, (3a.alpha.,4.beta.,5.alpha.,7.beta.,7a.alpha.)- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.



● HCl

L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1977:501484 CAPLUS
 DOCUMENT NUMBER: 87:101484
 TITLE: NMR investigation of dicyclopentadiene derivatives.
 III. Stereochemical classification of bridged
 endo-dicyclopentadiene derivatives and their
 Wagner-Meerwein rearrangement products by NMR
 spectroscopy
 AUTHOR(S): Kleinpeter, E.; Kuehn, H.; Muehlstaedt, M.
 CORPORATE SOURCE: Sekt. Chem., Karl Marx Univ., Leipzig, E. Ger.
 SOURCE: Org. Magn. Reson. (1977), 9(2), 90-7
 CODEN: ORMRBD
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 AB The ¹H and ¹³C NMR spectra of 18 oxa- and azatetracycloundecanes are
 reported. The ¹H NMR spectra are analyzed using spin decoupling and
 lanthanide paramagnetic shift expts. The ¹³C resonances were assigned
 using known substituent effects and paramagnetic shift values. The detd.
 paramagnetic shift parameters are discussed with respect to their contact
 and pseudocontact contributions.
 IT **63974-53-8**
 RL: PRP (Properties)
 (carbon-13 and proton NMR of)
 RN 63974-53-8 CAPLUS
 CN 2,4-Methanopentaleno[1,6-bc]pyrrole, 1-(3,5-dinitrobenzoyl)decahydro-
 (9CI) (CA INDEX NAME)



=>

---Logging off of STN---


=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	49.47	195.09
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.82	-7.41

STN INTERNATIONAL LOGOFF AT 08:27:50 ON 17 OCT 2002



exo/endo-(3-methoxybenzyl)(octahydro-4,7-methanoinden-5-yl)amine

Caution: Stereochemical terms discarded: exo, endo